Mirae Asset Global Investments Co. Ltd. Purchases 394 Shares of Verona Pharma PLC American Depositary Share $VRNA

Mirae Asset Global Investments Co. Ltd. grew its stake in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) by 3.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,880 shares of the company’s stock after purchasing an additional 394 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Verona Pharma PLC American Depositary Share were worth $1,124,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. NBC Securities Inc. acquired a new position in Verona Pharma PLC American Depositary Share during the 1st quarter worth approximately $34,000. Geneos Wealth Management Inc. lifted its stake in Verona Pharma PLC American Depositary Share by 44.2% in the first quarter. Geneos Wealth Management Inc. now owns 630 shares of the company’s stock worth $40,000 after acquiring an additional 193 shares during the period. Acadian Asset Management LLC purchased a new position in shares of Verona Pharma PLC American Depositary Share in the 1st quarter worth about $48,000. NewEdge Advisors LLC bought a new stake in Verona Pharma PLC American Depositary Share in the 1st quarter worth about $58,000. Finally, Advisors Preferred LLC grew its stake in shares of Verona Pharma PLC American Depositary Share by 65.4% during the 1st quarter. Advisors Preferred LLC now owns 1,599 shares of the company’s stock valued at $94,000 after purchasing an additional 632 shares during the period. 85.88% of the stock is owned by institutional investors.

Insider Transactions at Verona Pharma PLC American Depositary Share

In related news, Director Mahendra Shah sold 3,608 shares of the stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $13.14, for a total value of $47,409.12. Following the completion of the transaction, the director owned 93,472 shares of the company’s stock, valued at $1,228,222.08. This represents a 3.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO David Zaccardelli sold 208,912 shares of the company’s stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $13.14, for a total transaction of $2,745,103.68. Following the completion of the transaction, the chief executive officer owned 13,376,144 shares of the company’s stock, valued at approximately $175,762,532.16. This trade represents a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 540,584 shares of company stock worth $7,103,274. Company insiders own 4.80% of the company’s stock.

Verona Pharma PLC American Depositary Share Stock Performance

Verona Pharma PLC American Depositary Share stock opened at $106.91 on Friday. The stock has a market cap of $9.21 billion, a P/E ratio of -107.99 and a beta of 0.05. Verona Pharma PLC American Depositary Share has a 12 month low of $31.09 and a 12 month high of $106.93. The company’s fifty day simple moving average is $106.05 and its 200-day simple moving average is $88.80. The company has a quick ratio of 10.54, a current ratio of 10.71 and a debt-to-equity ratio of 0.87.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) last posted its quarterly earnings results on Wednesday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $0.14. Verona Pharma PLC American Depositary Share had a negative net margin of 36.62% and a negative return on equity of 21.12%. The firm had revenue of $103.14 million during the quarter, compared to analyst estimates of $90.41 million. As a group, sell-side analysts forecast that Verona Pharma PLC American Depositary Share will post -1.95 EPS for the current fiscal year.

Analysts Set New Price Targets

VRNA has been the subject of several recent analyst reports. Canaccord Genuity Group lowered shares of Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating and set a $107.00 price objective for the company. in a research note on Wednesday, July 9th. Cowen lowered Verona Pharma PLC American Depositary Share from a “buy” rating to a “hold” rating in a report on Wednesday, July 9th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $107.00 price target (down from $140.00) on shares of Verona Pharma PLC American Depositary Share in a research note on Wednesday, July 9th. HC Wainwright restated a “neutral” rating and issued a $107.00 target price (up previously from $90.00) on shares of Verona Pharma PLC American Depositary Share in a research report on Monday, July 14th. Finally, Wolfe Research cut Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 10th. Two analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $109.00.

Verona Pharma PLC American Depositary Share Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.